



US 20210255168A1


(19) **United States**(12) **Patent Application Publication**
ABU KHABAR(10) **Pub. No.: US 2021/0255168 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **A METHOD OF PRECISION CANCER THERAPY****Publication Classification**(71) Applicant: **KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE, RIYADH (SA)**(51) **Int. Cl.**
G01N 33/50 (2006.01)(52) **U.S. Cl.**
CPC G01N 33/5017 (2013.01); **G01N 2500/04** (2013.01)(72) Inventor: **KHALID S. ABU KHABAR, RIYADH (SA)**(57) **ABSTRACT**(21) Appl. No.: **16/973,573**(22) PCT Filed: **Jun. 13, 2019**(86) PCT No.: **PCT/EP2019/065585**

§ 371 (c)(1),

(2) Date: **Dec. 9, 2020****Related U.S. Application Data**

(63) Continuation-in-part of application No. 16/007,146, filed on Jun. 13, 2018.

The present invention relates to a method of treatment of cancer, said method comprising administering an effective dose of a protein kinase inhibitor to a patient in need thereof having said cancer. The present invention also relates to a method of post-transcriptional control of cancer-related genes comprising administering an effective amount of a protein kinase inhibitor to a subject in need thereof. The present invention further relates to a method of identifying a protein kinase inhibitor for normalizing post-transcriptional regulation as precision cancer therapy.

Specification includes a Sequence Listing.

B

87 KIs

| | | |
|----------|---------------------|---------|
| RPS30 Pr | dUW Nano luciferase | Control |
| RPS30 Pr | dUW Nano luciferase | ARE |

14 inhibitor